Navigation Links
Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Date:12/7/2008

llows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on Daiichi Sankyo, Inc., please visit www.dsus.com.

Forward-Looking Statements This news release may contain forward-looking statements based on current assumptions and forecasts made by Daiichi Sankyo group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports, which are available on the website at www.daiichisankyo-us.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

(1) Jorgensen, H.S., Nakayama, H, Reith, J. et. al. Acute stroke with atrial fibrillation. Stroke 1996;27: 1765-1769.

    (2) Hylek AM, et al. N Engl J Med. 2003; 349:1019-1026.


    Toshiaki Sai                                Dr. Felix Munzel
    Daiichi Sankyo Company, Limited (Tokyo)     Daiichi Sankyo Europe GmbH
    Phone: +81-3-6225-1126                      Phone: + 49-(0)-89-7808-471

    Kimberly Wix                                Dr. Thomas Portz
    Daiichi Sankyo, Inc. (Unit
'/>"/>
SOURCE  Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
3. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
8. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
9. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
10. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
11. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Reaching a critical milestone in the ... of Boards of Pharmacy ® (NABP ® ) ... has passed the Internet Corporation for Assigned Names and ... .PHARMACY gTLD by the end of 2013, and will ... and related entities that are located in ...
(Date:5/21/2013)... 21, 2013 Valeant Pharmaceuticals ... ) (TSX: VRX) today announced the ... its 2013 annual meeting of shareholders ... vote for the election of directors ... Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason Morfit235,623,2832,073,399J. ...
(Date:5/21/2013)... de 2013 La junta directiva de ... OMNIlife science®, Inc., Enztec, Ltd. y Praxim, SA, han ... Mayer, un ejecutivo ortopédico experimentado, será vicepresidente de ... , un experto refutado en dispositivos médicos, ... unirse a OSI como presidente de la junta, ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3
... DIEGO, Sept. 8 ResMed Inc. (NYSE: RMD ... company,s outstanding shares of common stock, payable in the form ... 2010. The new total shares outstanding doubled to 151,388,240 shares, ... the company,s common stock on the New York Stock Exchange ...
... 8 Transgenomic, Inc. (OTC Bulletin Board: ... chief executive officer, will deliver the Company,s corporate presentation ... Conference on Monday, September 13 at 4:55 p.m. EDT. ... in New York City from September 13th – 15th, ...
Cached Medicine Technology:Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 2Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 3
(Date:5/21/2013)... Mecklenburg EMS Agency (Medic) and the ... Community Wellness Fair to educate the public on health initiatives ... on Wednesday, May 22, 2013 from 4:00 pm until 7:00 ... Mallard Creek Road, Charlotte, NC 29262). , Medic, ... Mecklenburg County Department of Social Services are working ...
(Date:5/21/2013)... One-year results from SOURCE XT one of the ... reported today at EuroPCR 2013 show good clinical ... device success for all access approaches, valve sizes and ... up 2688 consecutively enrolled patients (mean age 81.5 years) ... 93 centres in 17 countries between July 2010 and ...
(Date:5/21/2013)... 2013 According to a May 13, 2013 ... of Botox,” Botox injections have become the most ... 2002 (Go to goo.gl/8iYbD). Although it is mostly associated with ... The injection makes facial wrinkles less visible by paralyzing facial ... about three months. This means that people who are conscious ...
(Date:5/21/2013)... Hillsboro, OR (PRWEB) May 21, 2013 ... curing systems at the 20th Annual IMI European ... As a proven market leader, Phoseon continues to invest ... while accelerating the adoption of UV LED curing in ... of product families on the market offering both air ...
(Date:5/21/2013)... May 21, 2013 MedMar Healing Center ... to benefit Second Harvest Food Bank. Twenty-eight businesses, including MedMar ... in the food drive. The goal is to raise food ... economic problems facing their families in recent years. , ... and help those in need,” explains Douglas Chloupek of MedMar ...
Breaking Medicine News(10 mins):Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2
... 4 Formerly conjoined twins,Yurelia and Fiorella Rocha-Arias ... are now home in Costa Rica. According to ... (30) and went,to Southern California to visit Mending ... trip. Today (4), they flew home,to San Jose, ...
... (Nasdaq: MLNM ) today announced that its ... will be webcast live and may be,accessed by ... http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ), ... the Company, VELCADE(R),(bortezomib) for Injection, other product candidates ...
... attractions when swallowed by kids, new report shows. , , MONDAY, ... a little boy who swallowed a magnet and wound up ... Jose, Calif., swallowed two tiny magnets from his older brother,s ... the first ingestion, he confessed to his mom, Jill Eberle, ...
... budget for fiscal year 2009, if enacted, would spell ... national effort to respond to the HIV/AIDS epidemic in ... flat-funds critical federal support for research at the National ... Centers for Disease Control and Prevention (CDC), and vital ...
... ... and Commit(R), PITTSBURGH, Feb. 4 GlaxoSmithKline ... cessation products in January 2008, which includes NicoDerm CQ,patches, Nicorette gum, and ... try and quit, unfortunately, many of them fail,without the proper tools and ...
... Costs, WASHINGTON, Feb. 4 The Pharmaceutical ... response to,the Federal Trade Commission,s (FTC) recent opposition ... corporate health care providers in,Puerto Rico to collectively ... comment from the FTC highlights the agency,s consistent,opposition ...
Cached Medicine News:Health News:Formerly Conjoined Twins Leave Packard Children's Hospital; Heading Home to Costa Rica 2Health News:BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation 2Health News:Toy Magnets Can be a Very Real Threat 2Health News:Toy Magnets Can be a Very Real Threat 3Health News:2009 Bush budget a disaster for HIV/AIDS 2Health News:One Million Boxes of Over-the-Counter Smoking Cessation Products Sold in January 2008 2Health News:One Million Boxes of Over-the-Counter Smoking Cessation Products Sold in January 2008 3
5 mm concave jaws, cross action....
... inserter is the first of its kind. ... through a minimal incision. The special direct-acting ... bag with complete control and predictability. The ... easy around-the-clock, and the instrument has a ...
... SI-30 and SI-40 foldable lenses through incisions as ... clear corneal and corneal scleral tunnels. The inserter ... rounded blades for a secure grasp of a ... a .15 millimeter notch which may be used ...
KR-8000 Supra is capable of obtaining perfectly accurate keratometry and/or refraction measurements through pupils as narrow as 2.0 mm....
Medicine Products: